Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Hepatitis B

In brief

The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are currently not being treated.

Key facts

Study ID

NCT02579382

Run by

Gilead Sciences

People needed

192

Starts

2015-11-10

Expected to finish

2019-05-03

Last updated by the study team

2020-05-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Los Angeles, California, United States
• Study site — Palo Alto, California, United States
• Study site — San Diego, California, United States
• Study site — San Francisco, California, United States
• Study site — Honolulu, Hawaii, United States
• Study site — Catonsville, Maryland, United States
• Study site — Boston, Massachusetts, United States
• Study site — Flushing, New York, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Toronto, Ontario, Canada
• Study site — Kowloon, Hong Kong
• Study site — Bologna, Italy
• Study site — Milan, Italy
• Study site — Pisa, Italy
• Study site — San Giovanni Rotondo, Italy
• Study site — Grafton, Auckland, New Zealand
• Study site — Daegu, South Korea
• Study site — Seoul, South Korea
• Study site — Dalin, Taiwan
• Study site — Kaohsiung City, Taiwan
• Study site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.